Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $200.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target lifted by HC Wainwright from $195.00 to $200.00 in a research report report published on Monday, Marketbeat.com reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q3 2026 earnings at $0.05 EPS, Q1 2027 earnings at $0.07 EPS, Q2 2027 earnings at $0.12 EPS, Q3 2027 earnings at $0.27 EPS, Q4 2027 earnings at $0.70 EPS and FY2027 earnings at $1.16 EPS.

A number of other analysts have also recently commented on MIRM. Citigroup reiterated a “buy” rating and issued a $160.00 target price (up from $145.00) on shares of Mirum Pharmaceuticals in a research note on Monday, September 28th. Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday, August 6th. Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Royal Bank Of Canada upped their price target on shares of Mirum Pharmaceuticals from $135.00 to $155.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Finally, UBS Group set a $137.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $147.88.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $79.96 on Monday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The business has a 50-day simple moving average of $93.70 and a two-hundred day simple moving average of $100.82. Mirum Pharmaceuticals has a fifty-two week low of $63.23 and a fifty-two week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The business had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. During the same quarter in the previous year, the firm posted ($0.12) EPS. Mirum Pharmaceuticals’s revenue was up 37.9% on a year-over-year basis. On average, equities analysts forecast that Mirum Pharmaceuticals will post -1.31 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total value of $2,960,400.00. Following the transaction, the chief executive officer directly owned 194,440 shares of the company’s stock, valued at approximately $19,187,339.20. This represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the completion of the transaction, the chief financial officer owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. The trade was a 14.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 98,499 shares of company stock worth $9,797,834. 8.32% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC boosted its position in Mirum Pharmaceuticals by 14.5% in the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after purchasing an additional 880,505 shares in the last quarter. Jupiter Topco LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $691,672,000. BlackRock Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $513,945,000. William Blair Investment Management LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $164,453,000. Finally, Rock Springs Capital Management LP increased its holdings in shares of Mirum Pharmaceuticals by 6.4% during the 1st quarter. Rock Springs Capital Management LP now owns 811,294 shares of the company’s stock valued at $74,947,000 after purchasing an additional 49,000 shares in the last quarter.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum’s Livmarli achieved the primary goal of the Phase III EXPAND study in ultra-rare liver diseases, improving cholestatic itching and reducing serum bile acids. The company plans to submit the data to the FDA in 2027, potentially expanding Livmarli’s addressable market. Mirum’s Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
• Positive Sentiment: Citigroup reportedly sees substantial upside potential for MIRM, reinforcing the longer-term investment case. Citigroup Forecasts Strong Price Appreciation for Mirum Pharmaceuticals
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $200 price target, well above the stock’s recent trading level. However, the firm lowered its FY2027 EPS forecast to $1.16 from $1.42 and reduced estimates for Q3 2026, Q1 2027, Q2 2027 and Q4 2027. The changes suggest continued confidence in Mirum’s long-term opportunity but a more cautious view of near-term earnings.
• Negative Sentiment: The repeated earnings-estimate cuts could weigh on the stock because they reduce projected profitability and may signal slower-than-expected commercialization, expenses, or revenue growth. Investors may focus on whether Mirum can convert Livmarli’s clinical progress into stronger financial results.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.